GLP-1 Around Labor & C-Section: Washout + Safety (2026)

If you take a GLP-1 — Ozempic, Wegovy, semaglutide, Mounjaro, Zepbound, tirzepatide — and you're searching about labor, delivery, or a C-section, here's the honest framing most people miss: in almost every case you should already be off the drug long before you get to the delivery room. GLP-1 medications are not used during pregnancy. The FDA labels tell patients to stop semaglutide at least 2 months before a planned pregnancy because the drug clears the body slowly (Wegovy / Ozempic / Rybelsus DailyMed §8.3 ^[9][11]), and the labels state these drugs should be used in pregnancy only if a clear benefit justifies the risk (Mounjaro DailyMed §8.1 ^[10]). So for a planned pregnancy, the washout is done months before labor and the intrapartum aspiration question is largely moot. The part that actually matters is the exception: if you conceived while still on a GLP-1, or used one late into pregnancy before stopping, what does that mean for anesthesia at a C-section? The reassuring answer is that obstetric anesthesia already treats every laboring patient as a high-aspiration-risk “full stomach” — a GLP-1 fits inside that existing safety framework rather than breaking it. This article walks through the washout timing and the intrapartum picture. For the egg-retrieval version of this question, see GLP-1 before IVF egg retrieval anesthesia, and for general surgery, holding a GLP-1 before surgery.

The honest summary

• You should already be off it. GLP-1s are not pregnancy drugs. FDA labels tell patients to discontinue semaglutide at least 2 months before a planned pregnancy because of its long washout, so by the time you reach labor the drug is normally long gone (Wegovy / Ozempic / Rybelsus DailyMed §8.3 ^[9][11]).
• If you conceived on a GLP-1, stop and tell your obstetric team. The labels say these drugs should be used in pregnancy only if benefit clearly justifies risk, so the usual step once pregnancy is confirmed is to stop the drug and let the prescriber and OB coordinate (Mounjaro DailyMed §8.1 ^[10]; Ozempic/Rybelsus DailyMed §8.3 ^[11]).
• The intrapartum aspiration concern is built into routine obstetric care already. Anesthesiologists treat all laboring patients as “full stomach,” high-aspiration-risk — labor slows gastric emptying, the uterus raises abdominal pressure, and the lower esophageal sphincter relaxes. A recent GLP-1 simply reinforces a precaution that is already standard, it does not create a brand-new one.
• Neuraxial anesthesia (epidural/spinal) is the default for C-section — and it avoids the airway and the deep sedation where aspiration risk is greatest. That is one reason maternal aspiration deaths have become very rare.
• GLP-1 delays gastric emptying. In surgical/endoscopy data, recent GLP-1 use raised the odds of retained stomach contents about 4.5-fold, but pooled data did not show more aspiration pneumonia (Baig 2025 ^[1]). A one-week hold may not fully empty the stomach either (Santos 2024 ^[4]).
• Inadvertent early-pregnancy exposure: the data so far are reassuring but limited. A six-center prospective cohort found no clear signal of increased major malformations after first-trimester GLP-1 exposure (Dao 2024 ^[7]), echoed by regulatory trial safety data (Parker 2025 ^[8]) — but samples are small, so this is “don't panic,” not “proven safe.”
• Bottom line: don't self-manage this. Coordinate any GLP-1 question with your prescriber and your obstetric/anesthesia team. Tell them exactly which drug, what dose, and when you last took it.

Why washout, not labor-day timing, is the real question

The most important thing to understand is that GLP-1 receptor agonists are not medications you stay on through pregnancy. They are weight-loss and diabetes drugs whose labels explicitly steer patients off well before conception. The FDA-approved prescribing information for semaglutide instructs patients to discontinue at least 2 months before a planned pregnancy “due to the long washout period for semaglutide” — semaglutide has a half-life of roughly a week, so it takes weeks to clear (Ozempic / Rybelsus DailyMed §8.3 ^[11]; Wegovy DailyMed §8.3 ^[9]). The pregnancy section of these labels (§8.1) adds that available human data are insufficient to rule out fetal risk and that the drug should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus; the tirzepatide (Mounjaro/Zepbound) label carries the same risk-summary stance (Mounjaro DailyMed §8.1 ^[10]).

What that means practically: for a planned pregnancy, the washout is finished months before you ever reach the delivery room. By the time of labor, delivery, or a scheduled C-section, the GLP-1 has long since cleared, and the intrapartum aspiration debate that dominates the surgery literature simply doesn't apply to you. The genuinely relevant scenarios are narrower: (1) you conceived unexpectedly while still taking a GLP-1, or (2) you used one later into the pregnancy than the label advises before stopping. In those cases the standard step is to stop the drug once pregnancy is recognized and bring your obstetric team into the loop — and then the anesthesia question becomes how a recent GLP-1 fits the care a laboring patient already receives.

If you conceived on a GLP-1: how it fits intrapartum anesthesia

Here is the part that should be genuinely reassuring. The reason GLP-1s worry anesthesiologists in the operating room is delayed gastric emptying — the same mechanism that curbs appetite can leave food or fluid in the stomach after a normal fast, raising a theoretical risk of regurgitating and aspirating contents during sedation. In the broader surgical and endoscopy literature, recent GLP-1 use was associated with roughly 4.5× the odds of retained gastric contents in a pooled analysis of 23 studies and 262,018 patients — although, importantly, that same analysis did not find a significant increase in actual aspiration pneumonia (Baig 2025 ^[1]). Prospective gastric-ultrasound and endoscopy studies confirm the direction of the “fuller stomach” effect (Silveira 2023 ^[5]; Sherwin 2023 ^[6]).

Now layer that onto obstetrics. Obstetric anesthesia already assumes every laboring patient has a full stomach and an elevated aspiration risk — and has for decades. From roughly 18–20 weeks of pregnancy onward, gastric emptying slows during labor, the growing uterus raises intra-abdominal pressure, and pregnancy hormones relax the lower esophageal sphincter, so a term patient is treated as high-risk regardless of how long she has fasted. The standard safeguards that flow from that assumption — restricting solids in active labor, antacid/acid-suppression prophylaxis, and, for general anesthesia, a rapid-sequence induction with a protected airway — are exactly the precautions that would mitigate a GLP-1's effect too. A recent GLP-1 doesn't introduce a new category of risk; it strengthens the case for the precautions already baked into how laboring patients are managed.

On top of that, the default anesthetic for a C-section is neuraxial — a spinal or epidural — not general anesthesia. Neuraxial techniques keep the patient awake with protective airway reflexes intact and avoid the deep sedation where aspiration is most dangerous. That preference for neuraxial over general anesthesia is one of the main reasons maternal deaths from aspiration have fallen to near-negligible levels over recent decades. So even in the uncommon case of recent GLP-1 exposure, the most common anesthetic path for a cesarean is the one that sidesteps the airway-aspiration scenario almost entirely.

Does a hold even empty the stomach? What the surgery data show

If you do reach a planned cesarean having used a GLP-1 more recently than ideal, you might assume that “just skip the last dose” fixes everything. The surgical data suggest it's not that simple. In Santos 2024 ^[4], among semaglutide users having upper endoscopy, stopping the drug for fewer than 8 days still left roughly a 10-fold higher chance of retained stomach contents, and 8–14 days about a 4.6-fold higher chance; only stopping for more than 14 days (in people without ongoing GI symptoms) brought the risk in line with non-users. This is one more reason the right move is to coordinate with your team rather than improvise — and it's also why the FDA's “months before conception” washout, when followed, removes the problem entirely. The strongest predictor of a fuller stomach in these studies was ongoing GI symptoms (nausea, vomiting, bloating, early fullness), so flag any of those to your team near your delivery date.

What if I was exposed early in pregnancy before I knew?

This is a separate worry from anesthesia, and it's the one many people are really asking about. Inadvertent first-trimester GLP-1 exposure is increasingly common because so many people of reproductive age take these drugs. The reassuring news is that the human data published so far have not shown a clear signal of harm. A multicentre, prospective observational cohort drawing on six Teratology Information Services compared GLP-1-exposed early pregnancies with comparison groups and did not find a clear increase in major birth defects (Dao 2024 ^[7]). Safety data pooled from the manufacturers' regulatory clinical-trial programs reached a broadly similar reassuring-but-limited conclusion (Parker 2025 ^[8]).

The crucial caveat: these datasets are still small, with wide confidence intervals, and they cannot rule out modest risks. That's why the labels and clinicians still advise stopping the drug once pregnancy is recognized and avoiding it during pregnancy rather than declaring it “safe” (Mounjaro DailyMed §8.1 ^[10]; Ozempic/Rybelsus DailyMed §8.3 ^[11]). If you were exposed before you knew you were pregnant, the appropriate response is to stop the drug and discuss it with your obstetric provider — not to assume the worst. For more on the preconception and washout picture, see Mounjaro pregnancy washout and preconception and the “Ozempic baby” fertility and pregnancy review.

What this means for you — the practical upshot

• Plan to be off the GLP-1 well before conception. The labels advise discontinuing semaglutide at least 2 months before a planned pregnancy because of its long washout — follow that and the intrapartum question essentially disappears (Wegovy / Ozempic / Rybelsus DailyMed §8.3 ^[9][11]).
• If you conceive on a GLP-1, stop the drug and tell your OB promptly. Don't keep dosing “until you can ask” and don't panic about exposure that already happened — bring it to your prescriber and obstetric team.
• For any delivery, tell anesthesia the exact drug, dose, and last-use date. Even though obstetric care already assumes a full stomach, a recent GLP-1 is information your team will want when individualizing precautions.
• Flag ongoing GI symptoms. Nausea, vomiting, bloating, or early fullness are the strongest predictors of retained stomach contents (Silveira 2023 ^[5]; Santos 2024 ^[4]); mention them near your delivery date.
• Know that neuraxial anesthesia is the C-section default — it keeps you awake with protective reflexes intact and avoids the highest-risk aspiration scenario.
• Follow your facility's written instructions. There is no GLP-1-specific obstetric protocol, so local judgment and your team's plan are what count.

Bottom line

For the overwhelming majority of patients, GLP-1 drugs and the delivery room never actually overlap: the FDA labels steer you to stop semaglutide at least 2 months before a planned pregnancy because of its slow washout, so the drug is normally long gone by labor (Wegovy / Ozempic / Rybelsus DailyMed §8.3 ^[9][11]; Mounjaro DailyMed §8.1 ^[10]). The narrow exception — conceiving while still on a GLP-1 — is handled by an existing, well-tested system: stop the drug when pregnancy is recognized, and rely on the fact that obstetric anesthesia already treats every laboring patient as a high-aspiration-risk full stomach, with neuraxial anesthesia as the cesarean default. GLP-1s do leave more in the stomach (Baig 2025 ^[1]; Santos 2024 ^[4]), but that hasn't translated into more aspiration pneumonia in the data, and inadvertent early-pregnancy exposure has so far looked reassuring though still under-studied (Dao 2024 ^[7]; Parker 2025 ^[8]). The single safest thing you can do is not decide alone: coordinate timing, washout, and any delivery plan with your prescriber and your obstetric/anesthesia team.

This article is educational and is not medical advice, and it is not a substitute for care from your obstetric, anesthesia, and prescribing clinicians. Pregnancy is a sensitive (“Your Money or Your Life”) topic; every claim above is sourced to an FDA-approved drug label (verified against the live DailyMed database), a society clinical practice document, or a peer-reviewed study verified against the live PubMed database before publication. Coordinate your own washout and delivery plan with your care team.